CN104693170A - Alkoxy thiophene amide double-target-point inhibitor and use thereof - Google Patents
Alkoxy thiophene amide double-target-point inhibitor and use thereof Download PDFInfo
- Publication number
- CN104693170A CN104693170A CN201510076732.3A CN201510076732A CN104693170A CN 104693170 A CN104693170 A CN 104693170A CN 201510076732 A CN201510076732 A CN 201510076732A CN 104693170 A CN104693170 A CN 104693170A
- Authority
- CN
- China
- Prior art keywords
- compound
- sglt2
- target
- sglt1
- point inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of type 2 diabetes related medicines and particularly relates to an alkoxyphenyl thiophene amide SGLT2/SGLT1 double-target-point inhibitor, a preparation method thereof and application of the double-target-point inhibitor in preparation of the type 2 diabetes related medicines. The double-target-point inhibitor has a structure represented by a formula shown in descriptions, wherein R1 is selected from methyl and ethyl.
Description
Technical field
The present invention relates to the pharmaceutical field of the treatment of diabetes B.Specifically, the present invention relates to the medicative class alcoxyl thiophene-carboxamides class SGLT2/SGLT1 of diabetes B two target spot inhibitor, its preparation method, and in purposes pharmaceutically.
Background technology
The metabolic disease of diabetes to be a kind of with hyperglycemia be feature.Hyperglycemia be then due to defect of insulin secretion or its biological action impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.There is no the method for radical cure diabetes at present, but suitably can be controlled diabetes progression by multiple treatment means.Mainly comprise several aspect: the education of diabetic subject, self-monitoring of blood glucose, dietetic treatment, exercise therapy and pharmacological agent.Oral hypoglycaemic medicine by a variety of, as sulfonylurea, biguanides, thiazolidinediones, glycosidase inhibitor class, etc., but these medicines generally have various different side effect, as hepatotoxicity, hypoglycemia, abdominal distension, heart disease risk, etc.Therefore the medicine of brand-new action target spot is active demand clinically.
Sodium-glucose co-transporters body (sodium-glucose linked transporter, SGLT) be a kind of glucose transporter, there are two kinds of hypotypes and SGLT1 and SGLT2, both all have distribution in renal proximal tubules, 10% and 90% are respectively to the contribution of glucose reabsorption in kidney, in addition SGLT1 is also distributed in enteron aisle, is responsible for the absorption of glucose in enteron aisle together with GLUT.Suppress SGLT2 that the glucose in uriniferous tubules can be made heavily not absorb smoothly enter blood and discharge with urine, thus reduce blood sugar concentration, the SGLT2 inhibitor of listing at present has multiple, as dapagliflozin, canagliflozin and empagliflozin etc.
Inhibitor of these listings are all optionally SGLT2 inhibitor, very weak to SGLT1 restraining effect.At the initial stage of SGLT2 inhibitor research and development, the selectivity of SGLT2/SGLT1 was once considered to very important index, because suppress SGLT1 may cause intestines and stomach side reaction in theory.But research in recent years shows, this theoretic worry there is no need, and confirm by the clinical trial of LX4211 (Zambrowicz B, et al.Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine in a dose-timing study in healthy subjects, Clin Ther., 2013, 35 (8), 1162-1173.e8).Because SGLT2/SGLT1 inhibitor can suppress SGLT1 further on the basis suppressing SGLT2, and this suppression can increase the discharge of glucose in urine in kidney and reduce the absorption of glucose in enteron aisle, therefore this kind of inhibitor is considered to a kind of selection of control blood sugar completely newly.
The invention discloses the two target spot inhibitor of a class alcoxyl thiophene-carboxamides class SGLT2/SGLT1, these compounds can be used for the medicine preparing treatment diabetes B.
Summary of the invention
An object of the present invention is to provide and a kind of there is the two target spot inhibit activities of good SGLT2/SGLT1, there is the non-glucoside compound of a class of general formula I.
Another object of the present invention is to provide the method that preparation has the compound of general formula I.
Another object of the present invention is to provide the application of compound in preparation treatment diabetes B medicine containing general formula I.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula I has following structural formula:
Wherein, R
1be selected from methyl, ethyl.
The compound of preferred following general formula I has following structure,
The compound of preferred following general formula I has following structure,
Compound II per changes the acyl chlorides III of its correspondence into; Acyl chlorides III reacts with compound IV in the presence of a base, obtains compound V; Compound V in the presence of a base with cyclopentadiene generation condensation reaction, obtain Compound I; Wherein R
1definition as previously mentioned.
Compound of Formula I of the present invention has the double inhibition effect of SGLT2/SGLT1, can be used as the medicine of effective constituent for the preparation of diabetes B.The activity of compound of Formula I of the present invention is verified by receptor binding assays.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
The synthesis of embodiment 1 Compound I-1
A. the synthesis of compound V-1
4.68g (20mmol) Compound II per-1 is dissolved in the methylene dichloride of 10mL drying, stirred at ambient temperature, slowly drip the oxalyl chloride of 3.81g (30mmol) newly distillation, then drip 2 DMF, then reaction mixture at room temperature stirs and spends the night.Reaction mixture is evaporate to dryness on a rotary evaporator, then in vacuum oil pump dry 5 minutes, dissolve with 10mL methylene dichloride again, ice-water bath cooling is lower stirs, then slowly drip 2.70g (20mmol) IV-1 and 6.07g (60mmol) triethylamine, dropwise rear reaction mixture at room temperature to stir and spend the night, TLC checks that reaction completes.After having reacted, pour in 100mL frozen water toward reaction mixture, stir, use the CH of 50mL × 3
2cl
2extraction, merges extraction phase, uses 1% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-1, white solid, ESI-MS, m/z=352 ([M+H]
+).
B. the synthesis of Compound I-1
The cyclopentadiene of 3.51g (10mmol) compound V-1 and 1.32g (20mmol) newly distillation is dissolved in 20 mL dehydrated alcohols, stir, add 3.40g (50mmol) solid sodium ethanol, continue stirring and spend the night under room temperature, TLC checks that reaction completes.Reaction mixture pours in 100mL frozen water, stirs, and uses the CH of 50mL × 3
2cl
2extraction, merges extraction phase, salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I-1, white solid, ESI-MS, m/z=400 ([M+H]
+).
Embodiment 2-6
With reference to embodiment 1 operation steps, synthesize compound listed in Table.
Embodiment 7 Compound ira vitro is to the suppression of people SGLT2 and people SGLT1
Prepared by people SGLT2 expression vector
To full length cDNA clone (purchased from GenScript company) (having put Hind III and Not I site at the cDNA two ends) subclone of people SGLT2 be expressed between the Hind III and Not I site of pEAK15 expression vector (Theracos company of the U.S.).The method of the clone's digestion with restriction enzyme containing target gene is determined.
Prepared by people SGLT2 stably transfected cell line
Utilize restriction enzyme Nsi I to digest the plasmid containing people SGLT2, make it linearizing, with agarose gel electrophoresis, purifying is carried out to linear DNA.With transfection reagent Lipofectamine2000 (Invitrogen company), the DNA after purifying is proceeded to HEK293 cell (Theracos company of the U.S.).By the cell after transfection containing 10% foetal calf serum DMEM substratum in 37 DEG C, 5%CO
2cultivate under condition after 24 hours, in identical growth medium, add purine mycin (Invitrogen company) continue cultivation 2 weeks, the cell after screening with puromycin-resistant is inoculated in (one, every hole cell) in 96 new orifice plates, cultivate in the substratum containing purinase element, until cell grows to converging state.There is the methyl-α-D-[U-of cell clone by reflection SGLT2 activity of puromycin-resistant
14c] pyranoside picked-up test screening (experimental technique has detailed description hereinafter) further.Select the cell clone with highest signal to noise ratio for follow-up methyl-α-D-[U-
14c] pyranoside picked-up test.
Prepared by people SGLT1 express cell
PDream2.1 expression vector containing total length people SGLT1cDNA is purchased from GenScript company.Plasmid increases in bacillus coli DH 5 alpha, and this strain culturing is in Luria-Bertani (LB) substratum containing penbritin.With QIAGEN Plasmid Midi test kit (QIAGEN company) extracting plasmid.With Lipofectamine 2000 transfection reagent, according to the method for operational manual, people SGLT1 expression vector plasmid is proceeded to COS-7 cell (purchased from American Type Tissue Collection).Transfectional cell in containing the DMEM of 10%DMSO in-80 DEG C of preservations.
Methyl-α-D-[U-
14c] pyranoside picked-up test
Before test, the DMEM of cell containing 10%FBS expressing SGLT1 and SGLT2 is respectively inoculated in 96 holes ScintiPlate liquid sudden strain of a muscle plate (PerkinElmer company), and (every hole adds 100 μ L nutrient solutions, containing 1 × 105 cell), and in 37 DEG C, cultivate 48 hours under 5%CO2 condition.Cell 150 μ L contain sodium damping fluid (137mM NaCl, 5.4mM KCl, 2.8mM CaCl
2, 1.2mM MgCl
210mM Tutofusin tris/N-2-hydroxyethyl piperazine-N '-ethane sulfonic acid [Tris/Hepes], pH7.2) or without sodium damping fluid (137mM N-methyl-glucamine, 5.4mM KCl, 2.8mM CaCl2,1.2mM MgCl2,10mM Tris/Hepes, pH7.2) wash twice.Testing compound is dissolved in containing 25% human plasma and 40 μ Ci/mL methyl-α-D-[U-
14c] pyranoside (Amersham Biosciences/GE Healthcare) containing sodium or without in sodium damping fluid, be prepared into the testing compound solution of a series of suitable concn.The 96 every holes of orifice plate add 50 μ L testing compound solutions, shaking culture 2 hours (SGLT1 analysis) or 1.5 hours (SGLT2 analysis).Cell 150 μ L cleaning buffer solution (137mM N-METHYL-ALPHA-L-GLUCOSAMINEs, 10mM Tris/Hepes, pH7.2) wash twice, with TopCount liquid scintillation counter (Perkin Elmer company), quantitative analysis is carried out to the picked-up of methyl-α-D-[U-14C] pyranoside.Sodium dependency pyranoside intake is the difference (mean value of three wells) deducting the intake obtained without the process of sodium damping fluid by the intake obtained containing the process of sodium damping fluid.
Shown in the following list of result.
The IC that part of compounds of the present invention suppresses people SGLT2 and people SGLT1
50value
| Compound | IC 50(hSGLT2,nM) | IC 50(hSGLT1,nM) |
| dapagliflozin | 1.4 | 1339 |
| Embodiment 1 compound | 8.1 | 13.5 |
| Embodiment 2 compound | 10.7 | 17.4 |
| Embodiment 3 compound | 9.7 | 17.2 |
| Embodiment 4 compound | 11.5 | 19.0 |
| Embodiment 5 compound | 10.4 | 17.8 |
| Embodiment 6 compound | 12.2 | 19.3 |
[0040]above-mentioned IC
50measurement result show, compound of the present invention is the two target spot inhibitor of strong SGLT2/SGLT1, can be used for preparing the medicine for the treatment of diabetes B.
Claims (4)
1. there is the compound of general formula I,
Wherein, R
1be selected from methyl, ethyl.
2. the compound of Formula I that defines of claim 1, is selected from following compounds,
3. synthesize arbitrary the defined method belonging to the compound of general formula I of claim 1-2:
Compound II per changes the acyl chlorides III of its correspondence into; Acyl chlorides III reacts with compound IV in the presence of a base, obtains compound V; Compound V in the presence of a base with cyclopentadiene generation condensation reaction, obtain Compound I; Wherein R
1definition as arbitrary in claim 1-2 as described in.
4. the compound of Formula I that one of claim 1-2 defines is preparing the application in treatment diabetes B medicine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510076732.3A CN104693170A (en) | 2015-02-11 | 2015-02-11 | Alkoxy thiophene amide double-target-point inhibitor and use thereof |
| CN201611193769.5A CN106632234A (en) | 2015-02-11 | 2015-02-11 | Alcoxyl thiophene amide double-target inhibitor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510076732.3A CN104693170A (en) | 2015-02-11 | 2015-02-11 | Alkoxy thiophene amide double-target-point inhibitor and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611193769.5A Division CN106632234A (en) | 2015-02-11 | 2015-02-11 | Alcoxyl thiophene amide double-target inhibitor and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104693170A true CN104693170A (en) | 2015-06-10 |
Family
ID=53340763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510076732.3A Pending CN104693170A (en) | 2015-02-11 | 2015-02-11 | Alkoxy thiophene amide double-target-point inhibitor and use thereof |
| CN201611193769.5A Pending CN106632234A (en) | 2015-02-11 | 2015-02-11 | Alcoxyl thiophene amide double-target inhibitor and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611193769.5A Pending CN106632234A (en) | 2015-02-11 | 2015-02-11 | Alcoxyl thiophene amide double-target inhibitor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104693170A (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007022258A1 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity thiophene-based and furan-based kinase ligands |
| BRPI0713058A2 (en) * | 2006-06-29 | 2012-04-10 | Taisho Pharmaceutical Co., Ltd. | c-phenyl 1-thioglycitol compound |
| CN101959515B (en) * | 2008-02-25 | 2013-06-12 | 默克专利有限公司 | Glucokinase activators |
-
2015
- 2015-02-11 CN CN201510076732.3A patent/CN104693170A/en active Pending
- 2015-02-11 CN CN201611193769.5A patent/CN106632234A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106632234A (en) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grempler et al. | Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter | |
| CN104725347A (en) | Alkoxy-substituted compounds containing methoxyphenyl thiophene amide structures and application | |
| CN104672207B (en) | The two target spot inhibitor of a kind of nitrothiophene acid amides toluene class and purposes thereof | |
| CN104693170A (en) | Alkoxy thiophene amide double-target-point inhibitor and use thereof | |
| CN104693172A (en) | Phenyl thiophene amide SGLT2/SGLT1 double-target-point inhibitor and use thereof | |
| CN104693171A (en) | Methoxyphenyl-containing thiophene amide structured double-target-point inhibitor and use thereof | |
| CN104610224A (en) | Halogenated phenyl thiophene amide type double-target-point inhibitor and application of halogenated phenyl thiophene amide type double-target-point inhibitor | |
| CN104610223A (en) | Thiophene amide toluene type SGLT2/SGLT1 double-target point inhibitor and application thereof | |
| CN104710403A (en) | Halogeneated thiophene amide methylbenzene dual-target-spot inhibitors and application thereof | |
| CN104693168A (en) | Nitrilyl thiophene amide toluene double-target-point inhibitor and use thereof | |
| CN104693169A (en) | Nitro substituted methoxyphenyl thiophene amide double-target-point inhibitor and use thereof | |
| CN104725346A (en) | Cyano-substituted double-target inhibitors containing methoxybenzene thiophene amide and application thereof | |
| CN104628671B (en) | Containing oil of mirbane thiazole carboxylic acid amides compounds and the purposes of benzene carbon amidine structure | |
| CN104610190B (en) | One class contains halogenophenyl thiazole carboxylic acid amides's compounds and the purposes of cyclopropyl amidine structure | |
| CN104610187B (en) | One class is containing alkoxyphenyl radical thiazole carboxylic acid amides class two target spot inhibitor, the Preparation Method And The Use of amidine structure | |
| CN104557766A (en) | Nitrobenzene thiazolecarboxylic acid amide compounds containing tert-butylformamidine structure and application thereof | |
| CN104628673A (en) | Nitrile benzene thiazolecarboxamide type compound containing tert-butylamidine structure and application thereof | |
| CN104592148A (en) | Cyclopropyl amidine structure containing nitrobenzene thiazolecarboxylic acid amide compound and application thereof | |
| CN104592151A (en) | Tert-butyl amidine structure containing SGLT2/SGLT1 dual-target inhibitor and application thereof | |
| CN104610188A (en) | Nitrile benzene thiazolecarboxamide type compound containing phenyl amidine structure as well as preparation method and application thereof | |
| CN104610189A (en) | SGLT2/SGLT1 double-target-point inhibitor containing cyclopropyl amidine structure and application of SGLT2/SGLT1 double-target-point inhibitor | |
| CN104592150A (en) | Cyclopropyl amidine structure containing cyanobenzene thiazolecarboxylic acid amide compound and application thereof | |
| CN104672164A (en) | SGLT2/SGLT1 double-target inhibitor containing benzene amidine structure as well as preparation method and application of inhibitor | |
| CN104710382A (en) | Halogeneated phenyl thiazole carboxylic acid amides compounds containing tertiary butyl amidine structures and application | |
| CN104672165B (en) | One class is containing alkoxyphenyl radical thiazole carboxylic acid amides's class two target spot inhibitor, the Preparation Method And The Use of cyclopropyl amidine structure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150610 |
|
| RJ01 | Rejection of invention patent application after publication |